Shan et al. validated PTEN as a target of miR-148b-3p; the negative dysregulation of PTEN promoted metastasis, EMT, and resistance to doxorubicin and paclitaxel both in in vitro assays using bladder cancer cells and in in vivo assays using a xenograft mouse model. The gene discussed is PTEN; the disease is urinary bladder cancer.